Treatment of climacteric syndrome of moderate severity with drug Lignarius-7 hydroxymatairesinol potassium acetate (HMR/lignan)

Introduction. The treatment of climacteric syndrome involves the menopausal hormone therapy. However, there are some contraindications to MGT. Because the alternative methods of correction of CS are needed. First of all, these are phytopreparations. Objective. To evaluate the efficacy and safety of various doses of the phytopreparation 7-hydroxymatairesinol (7HMR) in the treatment of climacteric syndrome of moderate severity. Material and methods. The randomized placebo-controlled study involved 60 women with a CS of moderate severity. Patients were divided into three groups: I group consisted of 20 patients who received the preparation of 7-hydroxymatairesinol J capsule J once a day; II group - 20 patients, who received the preparation of 7-hydroxymatairesinol 2 capsules once a day; III group - 20 patients, who received placebo one capsules once a day. Results. Analysis of the intensity of the hot flushes showed that after three months of therapy the frequency of the hot flushes decreased in all group: the group I (7-hydroxymatairesinol J capsule once a day) by 45 %; the group II (7-hydroxymatairesinol 2 capsules once a day) by 65 %; in the placebo group by 25 %. It is worth noting, the II group the frequency of the hot flushes decreased by 20 % more than in the I group. After evaluating the dynamics of psychoemotional symptoms in women with CS, we found positive dynamics after 3 months of treatment in group I of patients by 70 %, in the group II by 80 %, and in the placebo group all the symptoms decreased only by 20 %. Conclusions. The study showed that Lignarius was effective in relief of the hot flashes in both groups (45 and 65 % respectively). In the II group the efficiency was 20 % higher than in the group I, and significantly exceeded efficiency of placebo, where its was only 25 %. Lignarius also showed efficiency in relief of psychoemotional symptoms: in the I group it was 70 %, in the group II - 80 %, and in the placebo group - only 20 %. Discussion of the results. The study showed, the efficacy of Lignarius significantly differed from placebo in patients with the CS of moderate severity, and in the II group the efficacy was higher than in the I group. There are not data of hepatotoxicity and estrogenic effect of the 7-hydroxymatairesinol. We consider, the phytopreparation Lignarius may be used in the therapy for CS. It is an effective and safe phytopreparation.

menopause, climacteric syndrome, lignans, phytoestrogens

1. Балан В.Е., Ковалева Л.А., Рафаэлян И.В. «Роль негормональной терапии в лечении симптомов климактерического синдрома» Вопросы гинекологии, акушерства и перинатологии. 2012. Т. 11. № 5. С. 67-71.

2. Грезер Т., Циммерман Т., Шредер И. и др. Тенденции и перспективы гормонозамещения в период постменопаузы // Pharmedicum. 1993. № 1. С. 6.

3. Прилепская В.Н., Ледина А.В. Биоактивные компоненты растений и лечение климактерического синдрома // Акушерство и гинекология. 2011. № 7. С. 101-108.

4. Сметник В.П. Медицина климактерия. 2006. С. 50-67.

5. Сметник В.П. Приливы: загадка климактерия // Климактерий. Медицинский научно-реферативный журнал Российской ассоциации по менопаузе. 2009. № 1. С. 3-4.

6. Смирнов А.Н. Элементы эндокринной регуляции. М.: ГЭОТАР-Медиа, 2006. 352 с.

7. Katsuda S., Yoshida M., Saarinen N., Smeds A., Nakae D., Santti R., Maekawa A. Chemopreventive effects of hydroxymatairesinol on uterine carcinogenesis in Donryu rats. Exp Biol Med (Maywood). 2004; 229 (5): 417-424.

8. Udani J.K., Brown D.J., Tan M.O., Hardy M. Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study. J Am Coll Nutr. 2013; 32 (6): 428-35 doi.

9. Birge S.J. Estrogen and the brain: implications for menopause management // In: Menopause. The State of the Art-reserch and management / Ed. P.G. Schneider. The Parthenon Publishing Group, 2002. P. 191-195.

10. Green R.A. Measurement of estrogens effects on the brain using modern imaging techniques // Menopausal Med. 1999. Vol. 7. P. 9-12.

11. Brueggemeier R.W., Gu X., Mobley J.A., Joomprabutra S., Bbar A.S., Whetstone J.L. Effects of phytoestogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism // Ann. N.Y. Acad. Sci. V. № 948 (2001). P. 51-66.

12. Barry G.W. Socity, the menopause and hormone replacement therapy / Posgraduate Medicine, A special Report. 1990. Р. 9-13.

13. Yang D., Xiao C.X., Su Z.H., Huang M.W., Qin M., Wu W.J., Jia W.W., Zhu Y.Z., Hu J.F., Liu X.H. 7(S)-hydroxymatairesinol protects against tumor necrosis factor-alpha-mediated inflammation response in endothelial cells by blocking the MAPK/NF-kappaB and activating Nrf2/ HO-1. Phytomedicine. 2017; 32: 15-23 doi.

14. Freedman R.R. Menopausal hot flashes // In: Menopause: biology and pathobiology / Ed. R. Lobo, J. Kelsey, R. Marcus: 1 ed. / San Diego: Academic Press, 2000. P. 215-227.

15. Coker L.H., Espeland M.A., Rapp S.R., Legault C., Resnick S.M., Hogan P., Caussoin S., Dailey M., Shumaker S. A. 2010. Postmenopausal hormone therapy and cognitive outcomes: the Womens Health initiative Memory Sude (WHIMS). J. Steroid Biochem. Mol. Biol. 28 (118(4-5)). Р. 304-310.

16. Freeman E.W., Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review // Climacteric. 2007. № 10 (3). Р. 197-214.

17. Jokinen K., Rautava P., Makinen J. et. al. Experiense of climacteric symptoms among 42-46 and 52-56-year-old women // Maturitas. 2003. Vol. 46. P. 199.

18. Shively C.A., Bethea C.L. 2 004 Cognition, mood disorders, and sex hormones. Ilar J. 5 (2), Р. 189-199.

19. Bedell S., Nachtigall M., Naftolin F. The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol. 2014 Jan; 139: 225-36. doi: 10.1016/j.jsbmb.2012.12.004. Epub 2012 Dec 25.

20. Velde E.R., Van Leu Sden. Hormone treatment for the climacteric: alleviation of symptoms and prevention for postmenopausal disease. Lancet. 1994. Vol. 343. № 12. P. 654-657.

21. Spilioti E., Holmbom B., Papavassiliou A.G., Moutsatsou P. Lignans 7-hydroxymatairesinol and 7-hydroxymatairesinol 2 exhibit anti-inflammatory activity in human aortic endothelial cells. Mol Nutr Food Res. 2014; 58 (4): 749-59 doi.

22. Saarinen N.M., Huovinen R., Warri A., Makela S.I., Valentin-Blasini L., Needham L., Eckerman C., Collan Y.U., Santti R. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model. Nutr Cancer. 2001; 41 (1-2): 82-90.